Related Experiment Video

Updated: Jun 19, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Recombinant nematode anticoagulant protein c2 in non-ST segment elevation acute coronary syndrome and beyond

Adrian Fluture1, Gregory R Giugliano, Robert P Giugliano

  • 1Baystate Medical Center/Tufts Unicersity School of Medicine, 759 Chestnut Street, Springfield, MA 01199, USA.

Future Cardiology
|October 7, 2009
PubMed

Insights

Recombinant nematode anticoagulant protein (rNAP)c2 shows promise in reducing thrombin formation for acute coronary syndrome patients undergoing procedures. However, increased bleeding risk in bypass surgery necessitates further large-scale clinical trials.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) are associated with high rates of recurrent ischemic events.
  • Current guideline-based therapies do not fully mitigate these risks.
  • Novel anticoagulants are needed to improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant nematode anticoagulant protein (rNAP)c2 in patients with ACS.
  • To assess rNAPc2's impact on thrombin formation and bleeding rates.

Main Methods:

  • rNAPc2 inhibits the tissue factor/factor VIIa complex, acting proximally in the clotting cascade.
  • Administration can be intravenous or subcutaneous, with a half-life of 50-60 hours.
  • Studies included patients undergoing percutaneous coronary interventions (PCI) and non-ST segment elevation ACS with an early invasive strategy.

Main Results:

  • rNAPc2 effectively reduced thrombin formation in patients undergoing elective PCI and non-ST segment elevation ACS.
  • Bleeding rates were comparable to existing anticoagulants in these patient groups.
  • A significant increase in major bleeding was observed in patients undergoing emergent coronary artery bypass surgery within 96 hours of rNAPc2 dosing.

Conclusions:

  • rNAPc2 demonstrates potential as an anticoagulant for ACS patients, particularly those undergoing PCI.
  • Careful consideration of its use is required in patients requiring subsequent coronary artery bypass surgery due to elevated bleeding risk.
  • Further large-scale trials are essential to confirm clinical benefits and optimize its use in ACS management.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...